Clinical trials: Dyskinesia, Drug-Induced
Akathisia
Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation
Akathisia is a movement disorder that is often a side effect of certain psychiatric drugs. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace.
- Trial name
- NCT00065286
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Tardive Dyskinesia
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after…
- Trial name
- NCT05053321
- Testing
- Valbenazine
- Where
- United States
- Sponsor
- Yale University
Parkinson Disease, Dyskinesia, Drug-Induced
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
- Trial name
- STAT-PD (NCT04064294)
- Testing
- Intravenous Infusion
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Tardive Dyskinesia, Intellectual Disability
Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
The goal of this open-label clinical trial is to test the safety and efficacy of valbenazine treatment in patients with Intellectual/Developmental Disability (IDD) who have a diagnosis of Tardive dyskinesia (TD).
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06107829)
- Testing
- Valbenazine Oral Capsule
- Where
- United States
- Sponsor
- Stephen Ruedrich
Tardive Dyskinesia
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia.
- Trial name
- RIM-TD (NCT02198794)
- Testing
- SD-809
- Where
- 82 sites in United States, Czechia and 4 more
- Volunteers
- 343 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Parkinson's Disease, Dyskinesia
Capturing Parkinson's Disease Medication Side Effects During Daily Activities
The purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with Parkinson disease (PD) independent of voluntary activity…
- Trial name
- NCT01429207
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Tardive Dyskinesia
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
- Trial name
- NCT06011408
- Testing
- TDtect
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- iRxReminder
Movement Disorders, Essential Tremor
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of…
- Conditions
- Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease
- Trial name
- NCT02252380
- Testing
- Transcranial ExAblate System
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Parkinson's Disease
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is…
- Trial name
- NCT01092065
- Testing
- AFQ056 with L-dopa
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novartis
Tardive Dyskinesia
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
Tardive dyskinesia (TD) is a disabling, embarrassing and often irreversible iatrogenic movement disorder that can occur in anyone exposed to drugs that block dopamine receptors, including first and second generation…
- Trial name
- NCT03254186
- Testing
- Propranolol Hydrochloride
- Sponsor
- Emory University
Tardive Dyskinesia, Tardive Dystonia
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
Rationale: Tardive dyskinesia and dystonia (TDD) are severe side effects of dopamine blocking agents, particularly antipsychotics.
- Trial name
- NCT02524886
- Testing
- GPi DBS with Medtronic electorde and Activa PC pulsegenerator
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- GGZ Centraal
Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
- Trial name
- NCT01467089
- Testing
- Two way video assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.
Tardive Dyskinesia
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until…
- Trial name
- NCT02736955
- Testing
- Valbenazine
- Where
- 27 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurocrine Biosciences
Tourette Syndrome, Tardive Dyskinesia
Pimavanserin Treatment in TS
This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome.
- Trial name
- NCT04794413
- Testing
- Pimavanserin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Joseph Jankovic
Tardive Dyskinesia
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- KINECT 3 (NCT02274558)
- Testing
- NBI-98854
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 234 people
- Sponsor
- Neurocrine Biosciences
Dyskinesia, Medication-Induced, Parkinson's Disease
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's…
- Trial name
- NCT02657681
- Testing
- tSMS
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación de investigación HM
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals